Brevacizumab
Indications & Dose:
INDICATIONS
- Metastatic colorectal cancer, in combination with fluoropyrimidineirinotecan- or fluoropyrimidine- oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line Brevacizumab-containing regimen.
DOSAGE AND ADMINISTRATION
Metastatic colorectal cancer
- 5 mg/kg every 2 weeks with bolus-IFL
- 10 mg/kg every 2 weeks with FOLFOX4
- 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line Brevacizumab containing regimen First-line non"squamous non"small cell lung cancer
- 15 mg/kg every 3 weeks with carboplatin and paclitaxel Recurrent glioblastoma
- 10 mg/kg every 2 weeks Metastatic renal cell carcinoma
- 10 mg/kg every 2 weeks with interferon alfa Persistent, recurrent or metastatic cervical cancer (2.6)
- 15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan Stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection
- 15 mg/kg every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles Platinum-resistant recurrent epiyhelial ovarian, fallopian tube or primary peritoneal cancer
- 10 mg/kg every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan given every week
- 15 mg/kg every 3 weeks with topotecan given every 3 weeks Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
- 15 mg/kg every 3 weeks with carboplatin and paclitaxel for 6-8 cycles, followed by 15 mg/kg every 3 weeks as a single agent
- 15 mg/kg every 3 weeks with carboplatin and gemcitabine for 6-10 cycles, followed by 15 mg/kg every 3 weeks as a single agent Hepatocellular Carcinoma
- 15 mg/kg after administration of 1,200 mg of atezolizumab every 3 weeks Administer as an intravenous infusion.
Contraindications:
None
Side Effects:
-
Cautions:
-
Precautions:
-
Interaction:
-
Warnings:
WARNINGS AND PRECAUTIONS
- Gastrointestinal Perforations Fistula: Discontinue for gastrointestinal perforation, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ )
- Surgery and Wound Healing Complication: Discontinue in patients who develop wound healing complications that require medical intervention or necrotizing fasciitis. Withhold for at least 28 day prior to elective surgery. Do not administer Brevacizumab for at least 28 days after surgery and until the wound is fully healed
- Hemorrhage: Severe or fatal hemorrhages have occurred. Do not administer for recent hemoptysis. Discontinue for Grade 3-4 hermorrhage
- Arterial Thromboembolic Events (ATE): Discontinue for severe ATE.
- Venous Thromboembolic Events (VTE): Discontinue for Grade 4 VTE.
- Hypertension: Monitor blood pressure and treat hypertension. Withhold if not medically controlled resume once controlled. Discontinue for hypertensive crisis or hypertensive encephalopathy.
- Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue.
- Renal Injury and Proteinuria: Monitor urine protein. Discontinue for nephrotic syndrome. Withhold until less than 2 grams of protein in urine.
- Infusion-Related Reactions: Decrease rate for infusion-related reactions. Discontinue for severe infusion-related reactions and administer medical therapy.
- Embryo-Fetal Toxicity: May cause fetal harm. Advise females of potential risk to fetus and need for use of effective contraception.
- Ovarian Failure: Advise females of the potential risk.
- Congestive Heart Failure (CHF): Discontinue Brevacizumab in patients who develop CHF.
Adverse Effects:
-
Lactations:
-
Special Precautions:
-
Counselling:
-
Side Effects Or Adverse Reactions:
Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.
Patient And Carer Advice:
-